PD-L1 expression has been reported in 9.1–72.2% patients with biliary tract cancer6–8; thus, anti-PD-1 or PD-L1 agents can be a promising treatment modality in certain patients with biliary tract cancers. Here, CD274 is linked to biliary tract cancer.